This led to our hypothesis that combined inhibition of both JAK/STAT and mTOR pathways with next generation kinase inhibitors may be beneficial in patients with CRLF2-re or JAK2 driven Ph-like B-ALL. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.